P3-096: Phase II study of erlotinib in chemo–naïve women with advanced pulmonary adenocarcinoma.  by Jackman, David M. et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS720
P3-096 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
Phase II study of erlotinib in chemo-naïve women with advanced 
pulmonary adenocarcinoma.
Jackman, David M.1 Lindeman, Neal2 Lucca, Joan1 Morse, Linda K.1 
Rabin, Michael S.1 Marcoux, J. P.1 Huberman, Mark S.3 Johnson, Bruce 
E.1 Janne, Pasi A.1 
1 Dana-Farber Cancer Institute, Boston, MA, USA 2 Brigham and 
Women’s Hospital, Boston, MA, USA 3 Beth Israel Deaconess Medical 
Center, Boston, MA, USA 
Background: Erlotinib is associated with a survival beneﬁt over 
placebo for patients with advanced NSCLC who had received 1-2 prior 
regimens. Its therapeutic role as initial therapy in clinically deﬁned 
subgroups or in patients prospectively tested for EGFR mutations is 
less clear.
Methods: Chemotherapy-naïve women with adenocarcinoma, stage 
IIIB/IV, PS 0-1, who had never smoked or were former smokers, were 
enrolled and treated with erlotinib 150 mg PO daily, until the time of 
disease progression or unacceptable toxicity. Response rate was the 
primary endpoint. Secondary endpoints included overall survival, pro-
gression-free survival and toxicity. Tumor tissue adequate for genomic 
analysis was mandated and prospectively collected for analysis of 
EGFR and KRAS mutations by direct sequencing.
Results: From 11/04 to 10/06, 40 women were treated. Demograph-
ics: median age 65 yrs (range 36-87); 30% PS 0, 70% PS 1; 20% BAC 
or adenoCA with predominant BAC features, 80% adenoCA without 
BAC features; smoking status: 63% former, 37 % never. Toxicity: 
Rash (95%; 30% grade 3) and diarrhea (73%; 10% grade 3) were the 
most common toxicities. Half of pts developed a toxicity of grade 3 
or greater. 5 pts were discontinued due to toxicity, with 2 deaths that 
were potentially treatment-related: 1 DIC, 1 hepatic failure. There 
were also two pts with PE’s (one fatal). Response: CR 0, PR 12 (30%), 
SD 11 (28%), and PD 10 (25%), 7 not evaluable. To date, 27 patients 
have progressed, with 14 deaths. Median PFS was 5.6 months; median 
overall survival has not yet been reached and exceeds 23 months. Of 32 
patients sequenced for EGFR to date, there were 9 exon 19 deletions, 3 
L858R mutations, and 1 exon 20 insertion. For the 12 pts prospectively 
determined to have classic EGFR mutations, RR was 75% (9 PR, 2 SD, 
1 not evaluable). Of 15 pts w/ wild-type EGFR, only 1 response (7%) 
was achieved. The pt with the exon 20 insertion developed PD. Of 28 
pts evaluated to date for KRAS, 6 KRAS mutations were found, with 
no responses in this group (2 PD, 4 SD).
Conclusions: Preliminary results suggest that ﬁrst-line erlotinib mono-
therapy may be a useful treatment strategy for women with adenocar-
cinoma and a limited smoking history. Response rate is particularly 
impressive for those subjects prospectively found to have an EGFR 
mutation, and poor for those with KRAS mutations.
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Regressions 14 days following bevacizumab as a single agent as 
part of neoadjuvant chemotherapy for resectable non-squamous 
NSCLC
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Background: The addition of bevacizumab to standard chemotherapy 
improves response rate and overall survival in advanced non-squamous 
NSCLC, but limited data exist on response to treatment with bevaci-
zumab alone. As part of a trial evaluating bevacizumab with docetaxel 
and cisplatin (DC) as induction therapy for resectable stage IB-IIIA 
NSCLC, we determined the effect of single agent bevacizumab on 
tumor size 14 days following a single dose.
Methods: Eligibility was limited to patients with stage IB-IIIA resect-
able NSCLC. Patients with a contraindication to bevacizumab (squa-
mous histology, central tumor, hemoptysis) received only docetaxel 
(75 mg/m2) and cisplatin (75 mg/m2) q3 weeks for 4 cycles. If patients 
had no contraindications to bevacizumab, they underwent a baseline 
CT, a single dose of bevacizumab (15 mg/kg) on day 1, a second CT on 
day 14, and then 3 cycles of bevacizumab with docetaxel and cisplatin 
followed by one cycle without bevacizumab. WHO criteria were used 
to assess response. Following resection, patients in both arms received 
adjuvant bevacizumab for 1 year.
Results: 22 patients have been enrolled to date. Among the 13 patients 
who received induction bevacizumab, 10 had IIIA disease, 1 had IIB, 
and 2 had IB. The average reduction in tumor size (see ﬁgure) 14 days 
after bevacizumab alone was 13% (range +1.6% -24%). Among the 10 
who had surgery thus far, 6 had PR. Resections were R0 in 6 patients, 
R2 in 1, and not resectable for 2; 5 patients were downstaged. During 45 
cycles, there has been 1 episode of Grade 2 pre-operative hemoptysis, 
1 Grade 3 post-operative GI bleed, and 1 febrile neutropenia. Among 
patients receiving no induction bevacizumab, 4 had IIIA disease, 1 had 
IIB, and 3 had IB. All 8 of these patients had had surgery and 6 had PR. 
Resections were R0 in all cases; 5 were downstaged. The chemotherapy 
drug delivery was 95% for both preoperative treatment arms.
Conclusions: Treatment with a single dose of bevacizumab causes 
measurable decrease in tumor size in non-squamous NSCLC. The study 
is ongoing; we intend to determine the association between 14 day 
bevacizumab response and downstaging with neoadjuvant bevacizum-
ab/docetaxel/cisplatin, the primary endpoint of the study, to determine 
whether this measurement might serve as an early marker of biologic 
effect. Patient accrual continues. Supported by Genentech, Inc.
